Neovacs (LTS:0W8U) Other Current Payables: €0.00 Mil (As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0W8U Neovacs SA LTS:0W8U
4 GF Score
Price €16,000.00
View Full Analysis

What is Neovacs Other Current Payables?

Neovacs LTS:0W8U 4 Other Current Payables is €0.00 Mil as of Dec. 2024. GuruFocus rates LTS:0W8U with a GF Score™ of 4/100.

Neovacs's Other Current Payables for the quarter that ended in Dec. 2024 was €0.00 Mil.

Neovacs's quarterly Other Current Payables stayed the same from Dec. 2023 (€0.00 Mil) to Jun. 2024 (€0.00 Mil) but then increased from Jun. 2024 (€0.00 Mil) to Dec. 2024 (€0.00 Mil).

Neovacs's annual Other Current Payables stayed the same from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€0.00 Mil) but then increased from Dec. 2023 (€0.00 Mil) to Dec. 2024 (€0.00 Mil).

Neovacs Other Current Payables Related Terms

Neovacs Other Current Payables Historical Data

* Premium members only.

The historical data trend for Neovacs's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neovacs Other Current Payables Chart

Neovacs Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Neovacs Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LTS:0W8U
4GF Score
Neovacs SA LTS:0W8U
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neovacs Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of €0.00 Mil mean?
Neovacs (LTS:0W8U) has a Other Current Payables of €0.00 Mil as of Dec. 2024. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Neovacs and its competitors.
Is Neovacs' Other Current Payables too high?
Neovacs' current Other Current Payables is €0.00 Mil. Overall, Neovacs has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Neovacs' Other Current Payables compare to VRTX and REGN?
Neovacs' Other Current Payables of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Neovacs and its competitors. Neovacs's current Other Current Payables is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neovacs stock overvalued right now?
Neovacs (LTS:0W8U) has a current Other Current Payables of €0.00 Mil. The current Other Current Payables is €0.00 Mil. Neovacs' overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Neovacs (LTS:0W8U), the current Other Current Payables is €0.00 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neovacs Business Description

Address 3-5, Impasse Reille, Paris, FRA, 75014
Neovacs SA is a biotechnology company focused on the development of "Kinoids", therapeutic vaccines for the treatment of autoimmune, inflammatory diseases, allergies and cancer.
4GF Score

Get the complete analysis for LTS:0W8U

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€16,000.00
Price